Trevi Therapeutics faces earnings test as chronic cough trials advance

Trevi Therapeutics, a clinical-stage biotech company, is set to release third-quarter earnings after market close, with analysts predicting a loss of $0.13 per share. This would mark a widening from the $0.11 per-share loss reported in the previous quarter. Trevi is advancing Phase 3 trials for a therapy called Haduvio, which targets chronic cough related to idiopathic pulmonary fibrosis (IPF) and a refractory chronic cough in a Phase 2b trial.

The company has no current revenue as development continues, but its stock has seen a decline from its 52-week high of $20.22 to $14.33. Despite this, all 11 analysts covering the stock rate it as a Strong Buy, with a mean price target of $28.18, indicating a potential 97% upside. The fourth-quarter re-estimation of sample size for the LAKE trial in refractory chronic cough is a critical factor to watch.

If the trial continues without changes or increased enrollment, it would signal evidence of the drug's efficacy. Trevi faces less competition due to the recent termination of a competitor's RCC program following trial failure. With $319 million in cash on hand and a cash runway extending into 2030, investors will closely monitor the company's burn rate and funding adequacy for ongoing trials.

Haduvio is unique as it is the first investigational therapy to show a statistically significant reduction in cough frequency across both IPF and refractory chronic cough patient populations. The company has initiated the OCEAN-1 Phase 3 trial for IPF-related chronic cough and the LAKE Phase 2b trial for refractory chronic cough, with top-line results expected in 2027 and beyond.

The future success of Trevi's development timeline and cash management will be crucial in determining if the analyst community's bullish stance holds true.